CHINESE JOURNAL OF DRUG EVALUATION >

2026 , Vol. 43 >Issue 2: 133 - 133-137

DOI: https://doi.org/10.2095-3593.2026.040009

Effect of Anlotinib on the VEGF/VEGFR Pathway and Clinical Benefits in Refractory Differentiated Thyroid Cancer

  • 璐 杨
Expand
  • The Affiliated Hospital of Nanyang Medical College， Henan Nanyang 473000， China

Received date: 2025-10-28

  Revised date: 2025-12-31

  Accepted date: 2026-05-19

  Online published: 2026-05-19

Fold

Abstract

 Objective： To observe the effect of anlotinib on the VEGF/VEGFR pathway and clinical benefits in patients with refractory differentiated thyroid cancer（DTC）. Methods： A prospective study was conducted on 98 patients with refractory DTC who were treated in our hospital from May 2023 to May 2024， and a parallel controlled trial was designed. They were divided into the conventional group and the experimental group using a simple random grouping method， with 49 cases in each group. The conventional group was treated with RAI， while the experimental group was treated with anlotinib combined with RAI. The VEGF/VEGFR pathway proteins， tumor microenvironment， and tumor burden were compared between the two groups of patients. After one year of follow-up after treatment， the prognosis of the two groups of patients was compared. Analyze the correlation between VEGF/VEGFR and clinical indicators. Results： After treatment， the relative expression levels of VEGF and VEGFR in the experimental group were (1.66±0.35) and (1.52±0.41)， respectively， which were lower than those in the conventional group [(2.53±0.39)， (2.44±0.57)] (P<0.05). The levels of HIF-1α and CA9 in the experimental group were higher than those in the control group， while the levels of MMP2 and MMP9 were lower than those in the control group (P<0.05). The ORR and DCR of the experimental group were 79.59% (39/49) and 87.76% (43/49)， respectively， which were higher than those of the control group [55.10% (27/49)， 61.22% (30/49)] (P<0.05). As of the end of follow-up， the mPFS and mOS of the experimental group were higher than those of the control group (P<0.05). VEGF and VEGFR are negatively correlated with HIF-1 α and CA9， and positively correlated with MMP2 and MMP9 (r=-0.751， -0.822， 0.745， 0.816，-0.733，-0.806， 0.814， 0.795， P<0.05). Conclusion：Anlotinib improves the tumor microenvironment and reduces tumor burden in patients with refractory DTC， and has a positive impact on enhancing short-term survival benefits. Its mechanism of action may be related to the inhibition of VEGF/VEGFR pathway activity.

Key words： ; font-size:medium; ">Refractory differentiated thyroid cancer； Radioactive iodine therapy； Anlotinib； Vascular endothelial growth factor/vascular endothelial growth factor receptor； Clinical benefit

Cite this article

璐 杨 . Effect of Anlotinib on the VEGF/VEGFR Pathway and Clinical Benefits in Refractory Differentiated Thyroid Cancer[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026 , 43(2) : 133 -133-137 . DOI: 10.2095-3593.2026.040009

References

[1] 杨丽，柳春芳，王志恒. 超声造影定量参数联合外周血单个核细胞miR-34a、miR-146a对PTC诊断和淋巴结转移的评估价值[J]. 中南医学科学杂志，2024，52(3)：376-379.
     [2] 付豪，张亚娟，郭亚兰. 高频超声联合超声造影检查对甲状腺乳头状癌检出率的影响[J]. 黑龙江医学，2024，48(21)：2634-2636.
     [3] 吴耿刚. 甲状腺癌中血清miR-150-5p表达水平与临床病理特征的关系[J]. 华夏医学，2024，37(3)：221-226.
     [4] 张修志，翟慧萍，魏哲. 甲状腺癌组织HSP70表达与临床病理特征及术后复发的关联性分析[J]. 淮海医药，2024，42(4)：346-350.
     [5] 赵苗苗. 安罗替尼治疗难治性甲状腺癌的疗效及安全性分析[J]. 中国药物与临床，2023，23(5)：317-320.
     [6] Malekan M， Haass NK， Rokni GR， et al. VEGF/VEGFR axis and its signaling in melanoma： current knowledge toward therapeutic targeting agents and future perspectives[J]. Life Sci， 2024， 15(345)：122563.
     [7] Haddad RI， Bischoff L， Ball D， et al. Thyroid carcinoma， version 2.2022， NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw， 2022， 20(8)：925-951.
     [8] Sjoquist KM， Martin A， Pabvlakis N， et al. Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer[J]. J Cancer Res Clin Oncol， 2022， 10(31)：1-7.
     [9] Ach J， Vychopen M， Basaran AE， et al. Overall survival and progression-free survival in pediatric meningiomas： a systematic review and individual patient-level meta-analysis[J]. J Neurooncol， 2025， 172(2)：289-305.
     [10] 王苹，姚文娟，王丹，等. 甲状腺激素敏感性指标对老年分化型甲状腺癌术后复发转移的预测价值[J]. 中国医药，2025，20(10)：1494-1498.
     [11] 王龙. 分化型甲状腺癌患者全甲状腺切除术后并发症发生的独立危险因素分析[J]. 大医生，2025，10(18)：103-106.
     [12] 吕志祥，庞华，程刚，等. 18F-FDG PET/CT对碘-131难治性甲状腺癌的鉴别诊断价值[J]. 影像研究与医学应用，2025，9(13)：11-14.
     [13] 耿倩倩，杨爱民. 碘难治性分化型甲状腺癌的治疗进展及展望[J]. 中国癌症杂志，2025，35(1)：30-39.
     [14] Volpef， Nappi C， Zampellae， et al. Current advances in radioactive iodine-refractory differentiated thyroid cancer[J]. Curr Oncol， 2024， 31(7)：3870-3884.
     [15] Toro-Tobon D， Morris JC， Hilger C， et al. Clinical outcomes of radioactive iodine redifferentiation therapy in previously iodine refractory differentiated thyroid cancers[J]. Thyroid， 2024， 34(1)：70-81.
     [16] 汪显运，郭锋. 血清TGAb、TPOAb结合VEGF水平对分化型甲状腺癌近期预后不良的预测分析[J]. 贵州医药，2025，49(8)：1284-1287.
     [17] 李静娟. 安罗替尼联合131Ⅰ治疗分化型甲状腺癌51例效果及对患者疲乏程度、红细胞参数的影响[J]. 药品评价，2023，20(10)：1218-1221.
     [18] 钱蕾行，时鹤，柳卫. 安罗替尼治疗远处转移的放射性碘难治性分化型甲状腺癌的有效性及安全性[J]. 江苏医药，2025，51(6)：586-590.
     [19] 满国栋，王健力. 安罗替尼对进展性碘难治性分化型甲状腺癌疗效及生存时间的影响[J]. 中国药物应用与监测，2024，21(4)：354-358.
     [20] 赵苗苗. 安罗替尼治疗难治性甲状腺癌的疗效及安全性分析[J]. 中国药物与临床，2023，23(5)：317-320.
Options
Outlines

/

〈 〉

[an error occurred while processing this directive]